Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background/Objective: Medullary thyroid carcinoma (MTC) is a rare yet aggressive form of thyroid cancer comprising a disproportionate share of thyroid cancer-related mortalities, despite its low prevalence. MTC differs from other differentiated thyroid malignancies due to its heterogeneous nature, presenting complexities in both hereditary and sporadic cases. Traditional management guidelines, which are designed primarily for papillary thyroid carcinoma (PTC), fall short in providing the individualized care required for patients with MTC. In recent years, the sheer volume of data generated from clinical evaluations, radiological imaging, pathological assessments, genetic mutations, and immunological profiles has made it humanly impossible for clinicians to simultaneously analyze and integrate these diverse data streams effectively. This data deluge necessitates the adoption of advanced technologies to assist in decision-making processes. Holomics, which is an integrated approach that combines various omics technologies, along with artificial intelligence (AI), emerges as a powerful solution to address these challenges. Methods: This article reviews how AI-driven precision oncology can enhance the diagnostic workup, staging, risk stratification, management, and follow-up care of patients with MTC by processing vast amounts of complex data quickly and accurately. Articles published in English language and indexed in Pubmed were searched. Results: AI algorithms can identify patterns and correlations that may not be apparent to human clinicians, thereby improving the precision of personalized treatment plans. Moreover, the implementation of AI in the management of MTC enables the collation and synthesis of clinical experiences from across the globe, facilitating a more comprehensive understanding of the disease and its treatment outcomes. Conclusions: The integration of holomics and AI in the management of patients with MTC represents a significant advancement in precision oncology. This innovative approach not only addresses the complexities of a rare and aggressive disease but also paves the way for global collaboration and equitable healthcare solutions, ultimately transforming the landscape of treatment and care of patients with MTC. By leveraging AI and holomics, we can strive toward making personalized healthcare accessible to every individual, regardless of their economic status, thereby improving overall survival rates and quality of life for MTC patients worldwide. This global approach aligns with the United Nations Sustainable Development Goal 3, which aims to ensure healthy lives and promote well-being at all ages.
Background/Objective: Medullary thyroid carcinoma (MTC) is a rare yet aggressive form of thyroid cancer comprising a disproportionate share of thyroid cancer-related mortalities, despite its low prevalence. MTC differs from other differentiated thyroid malignancies due to its heterogeneous nature, presenting complexities in both hereditary and sporadic cases. Traditional management guidelines, which are designed primarily for papillary thyroid carcinoma (PTC), fall short in providing the individualized care required for patients with MTC. In recent years, the sheer volume of data generated from clinical evaluations, radiological imaging, pathological assessments, genetic mutations, and immunological profiles has made it humanly impossible for clinicians to simultaneously analyze and integrate these diverse data streams effectively. This data deluge necessitates the adoption of advanced technologies to assist in decision-making processes. Holomics, which is an integrated approach that combines various omics technologies, along with artificial intelligence (AI), emerges as a powerful solution to address these challenges. Methods: This article reviews how AI-driven precision oncology can enhance the diagnostic workup, staging, risk stratification, management, and follow-up care of patients with MTC by processing vast amounts of complex data quickly and accurately. Articles published in English language and indexed in Pubmed were searched. Results: AI algorithms can identify patterns and correlations that may not be apparent to human clinicians, thereby improving the precision of personalized treatment plans. Moreover, the implementation of AI in the management of MTC enables the collation and synthesis of clinical experiences from across the globe, facilitating a more comprehensive understanding of the disease and its treatment outcomes. Conclusions: The integration of holomics and AI in the management of patients with MTC represents a significant advancement in precision oncology. This innovative approach not only addresses the complexities of a rare and aggressive disease but also paves the way for global collaboration and equitable healthcare solutions, ultimately transforming the landscape of treatment and care of patients with MTC. By leveraging AI and holomics, we can strive toward making personalized healthcare accessible to every individual, regardless of their economic status, thereby improving overall survival rates and quality of life for MTC patients worldwide. This global approach aligns with the United Nations Sustainable Development Goal 3, which aims to ensure healthy lives and promote well-being at all ages.
The integration of artificial intelligence (AI) in cytopathology is an emerging field with transformative potential, aiming to enhance diagnostic precision and operational efficiency. This umbrella review seeks to identify prevailing themes, opportunities, challenges, and recommendations related to AI in cytopathology. Utilizing a standardized checklist and quality control procedures, this review examines recent advancements and future implications of AI technologies in this domain. Twenty-one review studies were selected through a systematic process. AI has demonstrated promise in automating and refining diagnostic processes, potentially reducing errors and improving patient outcomes. However, several critical challenges need to be addressed to realize the benefits of AI fully. This review underscores the necessity for rigorous validation, ongoing empirical data on diagnostic accuracy, standardized protocols, and effective integration with existing clinical workflows. Ethical issues, including data privacy and algorithmic bias, must be managed to ensure responsible AI applications. Additionally, high costs and substantial training requirements present barriers to widespread AI adoption. Future directions highlight the importance of applying successful integration strategies from histopathology and radiology to cytopathology. Continuous research is needed to improve model interpretability, validation, and standardization. Developing effective strategies for incorporating AI into clinical practice and establishing comprehensive ethical and regulatory frameworks will be crucial for overcoming these challenges. In conclusion, while AI holds significant promise for advancing cytopathology, its full potential can only be achieved by addressing challenges related to validation, cost, and ethics. This review provides an overview of current advancements, identifies ongoing challenges, and offers a roadmap for the successful integration of AI into diagnostic cytopathology, informed by insights from related fields.
As the pandemic continues to pose challenges to global public health, developing effective predictive models has become an urgent research topic. This study aims to explore the application of multi-objective optimization methods in selecting infectious disease prediction models and evaluate their impact on improving prediction accuracy, generalizability, and computational efficiency. In this study, the NSGA-II algorithm was used to compare models selected by multi-objective optimization with those selected by traditional single-objective optimization. The results indicate that decision tree (DT) and extreme gradient boosting regressor (XGBoost) models selected through multi-objective optimization methods outperform those selected by other methods in terms of accuracy, generalizability, and computational efficiency. Compared to the ridge regression model selected through single-objective optimization methods, the decision tree (DT) and XGBoost models demonstrate significantly lower root mean square error (RMSE) on real datasets. This finding highlights the potential advantages of multi-objective optimization in balancing multiple evaluation metrics. However, this study’s limitations suggest future research directions, including algorithm improvements, expanded evaluation metrics, and the use of more diverse datasets. The conclusions of this study emphasize the theoretical and practical significance of multi-objective optimization methods in public health decision support systems, indicating their wide-ranging potential applications in selecting predictive models.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.